The Role of Surgery in the Management of Epithelial Ovarian Cancer

被引:12
作者
Ramirez, Ingrid [1 ]
Chon, Hye Sook [2 ]
Apte, Sachin M. [2 ]
机构
[1] Univ S Florida, Dept Obstet & Gynecol, Tampa, FL 33620 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Womens Oncol, Tampa, FL 33612 USA
关键词
SECONDARY CYTOREDUCTIVE SURGERY; STAGE-III OVARIAN; CISPLATIN-BASED CHEMOTHERAPY; PREOPERATIVE SERUM CA-125; PRIMARY DEBULKING SURGERY; NEOADJUVANT CHEMOTHERAPY; INTRAPERITONEAL CISPLATIN; SURGICAL CYTOREDUCTION; PROGNOSTIC-FACTORS; PALLIATIVE SURGERY;
D O I
10.1177/107327481101800104
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Epithelial ovarian cancer is the most deadly gynecologic cancer in the United States. Multiple modalities of therapy are utilized in the management of the disease. The role of surgery remains important in the treatment of this disease and is described herein. Methods: Medline and PubMed were utilized to search the English language medical literature up to March 2010. A broad range of studies and quality of data were analyzed, including prospective studies, case control analyses, and meta-analyses. When possible, the highest level of evidence was reviewed and presented. Results: For the medically fit patient, optimal cytoreductive surgery positively impacts survival. For some highly selected patients, there is a role for a minimally invasive approach. In the recurrent setting, factors such as interval to recurrence and the distribution of disease will determine the utility of secondary cytoreductive surgery. A subgroup of patients may benefit from palliative surgical procedures in the recurrent setting. Conclusions: Despite advances in the use of chemotherapy and biologic agents, surgery remains an important modality in the diagnosis and treatment of ovarian cancer.
引用
收藏
页码:22 / 30
页数:9
相关论文
共 84 条
[1]   Second-look operation for epithelial ovarian cancer: Laparoscopy or laparotomy? [J].
AbuRustum, NR ;
Barakat, RR ;
Siegel, PL ;
Venkatraman, E ;
Curtin, JP ;
Hoskins, WJ .
OBSTETRICS AND GYNECOLOGY, 1996, 88 (04) :549-553
[2]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[3]   Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon [J].
Aletti, GD ;
Gostout, BS ;
Podratz, KC ;
Cliby, WA .
GYNECOLOGIC ONCOLOGY, 2006, 100 (01) :33-37
[4]   A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model [J].
Aletti, Giovanni D. ;
Santillan, Antonio ;
Eisenhauer, Eric L. ;
Hu, Jae ;
Aletti, Giacomo ;
Podratz, Karl C. ;
Bristow, Robert E. ;
Chi, Dennis S. ;
Cliby, William A. .
GYNECOLOGIC ONCOLOGY, 2007, 107 (01) :99-106
[5]   Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer [J].
Aletti, Giovanni D. ;
Dowdy, Sean C. ;
Podratz, Karl C. ;
Cliby, William A. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 197 (06) :676.e1-676.e7
[6]   Diagnostic open laparoscopy in the management of advanced ovarian cancer [J].
Angioli, R ;
Palaia, I ;
Zullo, MA ;
Muzii, L ;
Manci, N ;
Calcagno, M ;
Panici, PB .
GYNECOLOGIC ONCOLOGY, 2006, 100 (03) :455-461
[7]  
[Anonymous], 2000, Cochrane Database Syst Rev, DOI DOI 10.1002/14651858.CD002764
[8]  
Ansquer Y, 2001, CANCER, V91, P2329, DOI 10.1002/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.3.CO
[9]  
2-L
[10]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43